Literature DB >> 16021471

DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.

Oliver Bartsch1, Stefanie Schmidt, Marion Richter, Susanne Morlot, Eva Seemanová, Glenis Wiebe, Sasan Rasi.   

Abstract

Rubinstein-Taybi syndrome (RSTS) is a distinct dominant disorder characterized by short stature, typical face, broad angulated thumbs and halluces, and mental retardation. The RSTS can be caused by chromosomal microdeletions and molecular mutations in the CREBBP gene; however, relatively few mutations have been reported to date. Here, we aimed to determine the rate of point mutations and other small molecular lesions in true RSTS and possible mild variants, by using genomic DNA sequencing. A consecutive series of patients including 17 patients from our previous study was investigated. We identified 19 causative mutations of CREBBP in a total of 45 patients representing three different diagnostic groups: (a) 17 mutations in 30 patients with unequivocal RSTS (detection rate 56.6%), (b) two mutations in eight patients with features suggestive of RSTS ("moderate or incomplete RSTS", detection rate 25%), and (c) no mutation in seven patients with undiagnosed syndromes and isolated features of RSTS. In general, the mutations were distributed without hot spots and most were unique; however, three recurrent mutations (R370X, R1664H, and N1978S) were identified. Furthermore, we detected 15 different intragenic polymorphisms, including two non-synonymous coding polymorphisms, L551I and Q2208H. We report not only the highest detection rate (56.6%) of CREBBP mutations in patients with RSTS to date, but also the second missense mutation (N1978S) in a patient with moderate or incomplete RSTS. Previous studies have identified cytogenetic deletions in the CREBBP gene in eight to 12% of patients and very recently, Roelfsema et al. reported EP300 gene mutations in three of 92 (3.3%) patients with either true RSTS or different syndromes resembling RSTS. Our 56.6% detection rate of molecular mutations in CREBBP in patients with unequivocal RSTS supports the new concept that RSTS is a genetically heterogeneous disorder and furthermore, indicates that RSTS may be caused by gene/s other than CREBBP in up to 30% of cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021471     DOI: 10.1007/s00439-005-1331-y

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  23 in total

Review 1.  CBP/p300 in cell growth, transformation, and development.

Authors:  R H Goodman; S Smolik
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

2.  Molecular studies in 10 cases of Rubinstein-Taybi syndrome, including a mild variant showing a missense mutation in codon 1175 of CREBBP.

Authors:  O Bartsch; K Locher; P Meinecke; W Kress; E Seemanová; A Wagner; K Ostermann; G Rödel
Journal:  J Med Genet       Date:  2002-07       Impact factor: 6.318

3.  Rubinstein-Taybi syndrome in The Netherlands.

Authors:  R C Hennekam; M J Van Den Boogaard; B J Sibbles; H G Van Spijker
Journal:  Am J Med Genet Suppl       Date:  1990

4.  Keloids and neoplasms in the Rubinstein-Taybi syndrome.

Authors:  P A Siraganian; J H Rubinstein; R W Miller
Journal:  Med Pediatr Oncol       Date:  1989

5.  Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome.

Authors:  T Murata; R Kurokawa; A Krones; K Tatsumi; M Ishii; T Taki; M Masuno; H Ohashi; M Yanagisawa; M G Rosenfeld; C K Glass; Y Hayashi
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

6.  Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations.

Authors:  F Petrij; H G Dauwerse; R I Blough; R H Giles; J J van der Smagt; R Wallerstein; P D Maaswinkel-Mooy; C D van Karnebeek; G J van Ommen; A van Haeringen; J H Rubinstein; H M Saal; R C Hennekam; D J Peters; M H Breuning
Journal:  J Med Genet       Date:  2000-03       Impact factor: 6.318

7.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.

Authors:  Jeroen H Roelfsema; Stefan J White; Yavuz Ariyürek; Deborah Bartholdi; Dunja Niedrist; Francesco Papadia; Carlos A Bacino; Johan T den Dunnen; Gert-Jan B van Ommen; Martijn H Breuning; Raoul C Hennekam; Dorien J M Peters
Journal:  Am J Hum Genet       Date:  2005-02-10       Impact factor: 11.025

8.  A novel cryptic exon in intron 3 of the dystrophin gene was incorporated into dystrophin mRNA with a single nucleotide deletion in exon 5.

Authors:  Ryo Suminaga; Yasuhiro Takeshima; Kayo Adachi; Mariko Yagi; Hajime Nakamura; Masafumi Matsuo
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

9.  Hypertrichosis, hyperkeratosis, abnormal corpus callosum, mental retardation and dysmorphic features in three unrelated females.

Authors:  Minna H Pöyhönen; Maarit M Peippo; Leena K Valanne; Kirsti E Kuokkanen; Susanna M Koskela; Oliver Bartsch; Sasan Rasi; Glenis J Wiebe; Marketta Kähkönen; Helena A Kääriäinen
Journal:  Clin Dysmorphol       Date:  2004-04       Impact factor: 0.816

Review 10.  Long-range control of gene expression: emerging mechanisms and disruption in disease.

Authors:  Dirk A Kleinjan; Veronica van Heyningen
Journal:  Am J Hum Genet       Date:  2004-11-17       Impact factor: 11.025

View more
  38 in total

1.  Rubinstein-Taybi syndrome (CREBBP, EP300).

Authors:  Martine van Belzen; Oliver Bartsch; Didier Lacombe; Dorien J M Peters; Raoul C M Hennekam
Journal:  Eur J Hum Genet       Date:  2010-07-28       Impact factor: 4.246

2.  Translocations disrupting PHF21A in the Potocki-Shaffer-syndrome region are associated with intellectual disability and craniofacial anomalies.

Authors:  Hyung-Goo Kim; Hyun-Taek Kim; Natalia T Leach; Fei Lan; Reinhard Ullmann; Asli Silahtaroglu; Ingo Kurth; Anja Nowka; Ihn Sik Seong; Yiping Shen; Michael E Talkowski; Douglas Ruderfer; Ji-Hyun Lee; Caron Glotzbach; Kyungsoo Ha; Susanne Kjaergaard; Alex V Levin; Bernd F Romeike; Tjitske Kleefstra; Oliver Bartsch; Sarah H Elsea; Ethylin Wang Jabs; Marcy E MacDonald; David J Harris; Bradley J Quade; Hans-Hilger Ropers; Lisa G Shaffer; Kerstin Kutsche; Lawrence C Layman; Niels Tommerup; Vera M Kalscheuer; Yang Shi; Cynthia C Morton; Cheol-Hee Kim; James F Gusella
Journal:  Am J Hum Genet       Date:  2012-07-05       Impact factor: 11.025

3.  [Bony lacrimal duct stenosis and hand abnormalities as signs of systemic disease].

Authors:  J Heichel; T Bredehorn-Mayr; K Böhm; M Linné; S Riedel; H G Struck
Journal:  HNO       Date:  2016-06       Impact factor: 1.284

4.  Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300.

Authors:  Deborah Bartholdi; Jeroen H Roelfsema; Francesco Papadia; Martijn H Breuning; Dunja Niedrist; Raoul C Hennekam; Albert Schinzel; Dorien J M Peters
Journal:  J Med Genet       Date:  2007-01-12       Impact factor: 6.318

Review 5.  Epigenetic mechanisms in stroke and epilepsy.

Authors:  Jee-Yeon Hwang; Kelly A Aromolaran; R Suzanne Zukin
Journal:  Neuropsychopharmacology       Date:  2012-08-15       Impact factor: 7.853

6.  High frequency of copy number imbalances in Rubinstein-Taybi patients negative to CREBBP mutational analysis.

Authors:  Cristina Gervasini; Federica Mottadelli; Roberto Ciccone; Paola Castronovo; Donatella Milani; Gioacchino Scarano; Maria Francesca Bedeschi; Serena Belli; Alba Pilotta; Angelo Selicorni; Orsetta Zuffardi; Lidia Larizza
Journal:  Eur J Hum Genet       Date:  2010-02-03       Impact factor: 4.246

7.  Rubinstein-Taybi Syndrome Associated with Pituitary Macroadenoma: A Case Report.

Authors:  Yasamin Olyaei; J Manuel Sarmiento; Serguei I Bannykh; Doniel Drazin; Robert T Naruse; Wesley King
Journal:  Cureus       Date:  2017-04-11

8.  Mosaic CREBBP mutation causes overlapping clinical features of Rubinstein-Taybi and Filippi syndromes.

Authors:  Tamar I de Vries; Glen R Monroe; Martine J van Belzen; Christian A van der Lans; Sanne Mc Savelberg; William G Newman; Gijs van Haaften; Rutger A Nievelstein; Mieke M van Haelst
Journal:  Eur J Hum Genet       Date:  2016-03-09       Impact factor: 4.246

Review 9.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

10.  A Novel CREBBP in-Frame Deletion Variant in a Chinese Girl with Atypical Rubinstein-Taybi Syndrome Phenotypes.

Authors:  Qingming Wang; Wanfang Xu; Yanhui Liu; Haiming Yuan
Journal:  J Mol Neurosci       Date:  2020-08-25       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.